[翻译文章]西班牙多发性硬化症患者的疾病修饰性治疗方法
Alejandro Santiago Pérez1, Santos Esteban Casado1, Miriam Álvarez Payero2
1Servicio de Farmacia, Hospital Infanta Leonor, Madrid, Spain.
概括
这项研究分析了西班牙多发性硬化症患者的疾病修饰性治疗和多药学. 二甲基烟酸是最常见的,观察到显著的并发症和药物相互作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
- 公共卫生 公共卫生
背景情况:
- 多发性硬化症 (MS) 是一种慢性,致残的中枢神经系统疾病.
- 由于复杂的症状,MS患者经常经历高并发症和多药性.
研究的目的:
- 为了确定西班牙医院药房部门的疾病修饰治疗 (DMT) 类型.
- 在MS患者中描述并发治疗,多药,药物相互作用和药物治疗复杂性.
主要方法:
- 一项观察性,横截面的多中心研究包括1407名患有活跃DMT的多发性硬化症患者.
- 收集的数据包括DMT,并发症和并发药物.
- 使用药物治疗方案复杂性指数 (MRCI) 评估药物治疗复杂性.
主要成果:
- 丁甲基 fumarate (19.1%) 是最常被处方的DMT,其次是 teriflunomide (14.0%).
- 39.8%的患者至少有两种并发症,32.7%的患者经历过多种药物治疗.
- 药物相互作用的患病率为14.8%,中位数MRCI为8.0.
结论:
- 该研究提供了西班牙MS患者的DMT和相关复杂性的全面概述.
- 调查结果强调了并发症和多药物的重大负担,需要谨慎的药物管理.
关键词:
多发性硬化 多发性硬化西班牙西班牙西班牙西班牙西班牙西班牙多发性硬化症是多发性硬化症.多种药房 多种药房西班牙西班牙西班牙西班牙西班牙药物相互作用 药物相互作用药物相互作用如药物相互作用.多重病态性多重病态性多种多样性的多重性.多种药房 药房 多种药房更多相关视频
相关概念视频
Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...


